PHARMARON(300759) 中原证券·2024-11-08 12:01Investment Rating - The report assigns a "Buy" rating to the company, indicating an expected relative increase of over 15% compared to the CSI 300 index within the next 6 months [1][9] Core Views - The company's 3Q performance showed sequential improvement, with CMC new order growth accelerating [1] - The company's four major business segments are Laboratory Services, CMC Services, Clinical Research Services, and Large Molecule and Cell & Gene Therapy Services [1] - In the first three quarters of 2024, the company achieved revenue of 8.817 billion yuan, a year-on-year increase of 3.0%, and net profit attributable to the parent company of 1.422 billion yuan, a year-on-year increase of 24.8% [1] - The company's new order signings increased by over 18% year-on-year, with CMC new orders growing by over 30% [1][2] Business Segment Analysis Laboratory Services - Contributed 5.219 billion yuan in revenue in the first three quarters of 2024, a 2.95% year-on-year increase, with a gross margin of 44.76% [1] - New orders increased by over 12% year-on-year [1] - The company's drug safety evaluation laboratory passed national GLP certification in July 2024 [1] CMC Services - Generated 1.977 billion yuan in revenue in the first three quarters of 2024, a 3.29% year-on-year increase [1] - Third-quarter revenue reached 801 million yuan, a 34.9% sequential increase and 20.9% year-on-year growth [2] - New orders increased by over 30% year-on-year [2] Clinical Research Services - Achieved 1.306 billion yuan in revenue in the first three quarters of 2024, a 3.48% year-on-year increase [2] - Gross margin declined to 13.20%, down 5.04 percentage points year-on-year [2] Large Molecule and Cell & Gene Therapy Services - Recorded 311 million yuan in revenue in the first three quarters of 2024, a slight 0.11% year-on-year increase [2] - Gross margin was negative at -42.81%, primarily due to ongoing construction and investment phase [2] Financial Performance - The company's comprehensive gross margin for the first three quarters of 2024 was 33.87%, a decrease of 2.09 percentage points year-on-year [1] - Sales net margin increased to 15.53%, up 2.28 percentage points year-on-year [1] - The company's price-to-earnings ratio for 2024-2026 is projected at 31.58x, 28.17x, and 23.77x respectively [3][4] Future Outlook - The company is expected to achieve EPS of 0.98 yuan, 1.10 yuan, and 1.30 yuan for 2024-2026 [3] - Revenue is projected to grow from 12.190 billion yuan in 2024 to 16.302 billion yuan in 2026 [4] - Net profit is forecasted to increase from 1.751 billion yuan in 2024 to 2.326 billion yuan in 2026 [4]